Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 187 for “"Diffuse Large B Cell Lymphoma"”.
-
UNDERSTANDING DIFFUSE LARGE B-CELL LYMPHOMA RESISTANCE TOWARDS GEMCITABINE
The standard of care therapy for aggressive diffuse large B-cell lymphoma (DLBCL), R-CHOP, has broadly shown ineffectiveness to relapsed/refractory patients. However, alternative therapies, such as R-GemOx, still offers a poor overall survival rate. Hence, we aimed to investigate the cause of …
-
Tumour associated macrophages in Diffuse Large B cell lymphoma
… some of the mechanisms by which Burkitt lymphoma cells attract macrophages to the tumour and some of the mechanisms by which these macrophages support tumour cell growth. This thesis extends some of the work carried out in Burkitt lymphoma to Diffuse Large B cell lymphoma (DLBCL) and …
-
Osteopontin protects from autoimmunity-driven diffuse large B cell lymphoma development
… indeed a high risk of developing non-Hodgkin lymphoma (NHL), mostly diffuse large B cell lymphoma (DLBCL). Osteopontin (OPN) has been associated with SLE pathogenesis, as SLE patients have increased serum levels of OPN and often polymorphisms in <i>SPP1</i>, the gene encoding for OPN. …
-
Functional Drivers of Therapeutic Response in Diffuse Large B Cell Lymphoma
<p>Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma and a leading cause of death among B cell lymphomas. The disease displays a remarkable amount of genetic and clinical heterogeneity, hampering efforts at designing effective therapeutic agents. The last major …
-
Targeting Epigenetic Regulators For The Treatment of Diffuse Large B-Cell Lymphoma
… promise for the treatment of Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL). Compared to a 60% Objective Response Rate (ORR) in Phase I clinical trials, Phase II trial results for the EZH2 inhibitor EPZ-6438 reported an attenuation of response. Mechanisms contributing to …
-
Clonal relationship and mutational landscape of diffuse large B-cell lymphoma recurrences
Contains fulltext : 302711.pdf (Publisher’s version ) (Open Access)
-
Diffuse large B-cell lymphoma and red cell autoimmunity - clinical role and pathogenesis
Diffuse large B-cell lymphoma (DLBCL) is the most common form of B-cell non-Hodgkin lymphoma (B-NHL) and results in significant morbidity and mortality despite advancements in treatment. Lymphoma and autoimmune disease both result from breakdowns in normal cell regulatory pathways, and …
-
Identification and Functional Analysis of Epigenetic Alterations in Diffuse Large B cell Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common type of non- Hodgkin lymphoma accounting for around 30% of newly diagnosed cases per year. It is a very heterogeneous and aggressive disease, which arises from mature B-cells at different stages of differentiation and is characterized by a …
-
The role of NM23-H1/H2 proteins in diffuse large B-cell lymphoma
… that NM23-H1 plays important roles in normal cell development, differentiation and in cancer progression. It was found in previous studies that high expression of NM23-H1 protein is associated with poor prognosis and worse outcomes in diffuse large B-cell lymphoma (DLBCL). One possible …
-
Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms
Burkitt lymphoma (BL) is a rare, aggressive disorder constituting 1% of all non-Hodgkin lymphoma. Diffuse large B-cell lymphoma (DLBCL) is more common, accounting for 30% of malignant lymphoma. Standard treatment for adult BL and for certain subgroups of patients with DLBCL remains to be defined …
-
Prognostic Markers and Mechanisms of Chemotherapy Resistance in Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease. Identification of prognostic and predictive markers is important to design individualised and effective treatment strategies. This thesis describes different approaches to search for molecular prognostic markers and …
-
Cross-Talk Between Protein Degradation And Mrna Decay In Diffuse Large B-Cell Lymphoma
… plays a critical role in the maintenance of cellular homeostasis as it mediates the precise and temporal degradation of intracellular proteins and affects a variety of cellular processes. The misregulation of the ubiquitin-proteasome system (UPS) can result in the pathogenesis of human …
-
Mitochondrial biogenesis and pathway activation during follicular lymphoma transformation to diffuse large B-cell lymphoma
The full abstract for this thesis is available in the body of the thesis, and will be available when the embargo expires.
-
TARGETING DNA DAMAGE RESPONSE KINASES TO IMPROVE CHEMOTHERAPY EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA
Diffuse large B cell lymphoma (DLBCL) is the most common form of Non-Hodgkin’s Lymphoma, and about half of the patients relapse or are refractory to first line treatment, R-CHOP—an immunochemotherapy consisting of Rituximab and chemotherapy agents. Targeting the DNA Damage Response (DDR) pathway …
-
Functional consequences of transmembrane protein 30A (TMEM30A) inactivating mutations in diffuse large B-cell lymphoma
… WT TMEM30A. Presently, the role of TMEM30A in lymphomagenesis remains elusive. Therefore, this study aimed to clarify its biological function and significance in DLBCL. DOHH-2, a human DLBCL cell line was genetically modified to create several mutant clones with TMEM30A LOF. Specifically, a …
-
Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era
Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma and is characterized by marked clinical and genetic heterogeneity. Approximately 60% of patients with DLBCL are cured with multi-agent chemotherapy consisting of rituximab, cyclophosphamide, hydroxyldaunomycin, oncovin and …
Page 1 of 10